Ultra-low-dose estriol and Lactobacillus acidophilus vaginal tablets (Gynoflor®) for vaginal atrophy in postmenopausal breast cancer patients on aromatase inhibitors: pharmacokinetic, safety, and efficacy phase I clinical study
Gilbert Donders(Institut Scientifique de Santé Publique), Stefan Buchholz(University Hospital Regensburg), Patrick Neven(KU Leuven), Philipp Grob, Olaf Ortmann(University of Regensburg), M. Moegele(University Hospital Regensburg), Anneleen Lintermans(Universitair Ziekenhuis Leuven), Gert Bellen(Flemish Community), V. Prasauskas
Cited by 128
Related Papers
MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy
|Journal of Clinical Oncology|2017|1.7k
The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2
|JAMA Oncology|2019|1k
Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial
|The Lancet|2007|912
Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer
|New England Journal of Medicine|2018|684
Predictive value for preterm birth of abnormal vaginal flora, bacterial vaginosis and aerobic vaginitis during the first trimester of pregnancy
|BJOG An International Journal of Obstetrics & Gynaecology|2009|436